These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28965103)

  • 1. Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study.
    Zhang T; Kingwell E; Zhu F; Petkau J; Kastrukoff LF; Marrie RA; Tremlett H; Evans C
    BMJ Open; 2017 Sep; 7(9):e018612. PubMed ID: 28965103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study.
    Evans C; Tam J; Kingwell E; Oger J; ; Tremlett H
    Clin Ther; 2012 Feb; 34(2):341-50. PubMed ID: 22296946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between the use of selective serotonin reuptake inhibitors and multiple sclerosis disability progression.
    Zhang T; Kingwell E; De Jong HJ; Zhu F; Zhao Y; Carruthers R; Petkau J; Gustafson P; Oger J; Tremlett H
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1150-1159. PubMed ID: 27211481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
    Sayao AL; Devonshire V; Tremlett H
    Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural, innate improvements in multiple sclerosis disability.
    Tremlett H; Zhu F; Petkau J; Oger J; Zhao Y;
    Mult Scler; 2012 Oct; 18(10):1412-21. PubMed ID: 22736751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
    Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
    JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence and persistence to drug therapies for multiple sclerosis: A population-based study.
    Evans C; Marrie RA; Zhu F; Leung S; Lu X; Melesse DY; Kingwell E; Zhao Y; Tremlett H
    Mult Scler Relat Disord; 2016 Jul; 8():78-85. PubMed ID: 27456879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Socioeconomic status and disability progression in multiple sclerosis: A multinational study.
    Harding KE; Wardle M; Carruthers R; Robertson N; Zhu F; Kingwell E; Tremlett H
    Neurology; 2019 Mar; 92(13):e1497-e1506. PubMed ID: 30796140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome.
    Meyniel C; Spelman T; Jokubaitis VG; Trojano M; Izquierdo G; Grand'Maison F; Oreja-Guevara C; Boz C; Lugaresi A; Girard M; Grammond P; Iuliano G; Fiol M; Cabrera-Gomez JA; Fernandez-Bolanos R; Giuliani G; Lechner-Scott J; Cristiano E; Herbert J; Petkovska-Boskova T; Bergamaschi R; van Pesch V; Moore F; Vella N; Slee M; Santiago V; Barnett M; Havrdova E; Young C; Sirbu CA; Tanner M; Rutherford M; Butzkueven H;
    PLoS One; 2012; 7(6):e38661. PubMed ID: 22768046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
    JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication adherence and health outcomes in persons with multiple sclerosis treated with dimethyl fumarate.
    Jožef M; Locatelli I; Brecl Jakob G; Rot U; Kos M
    Mult Scler Relat Disord; 2023 Apr; 72():104615. PubMed ID: 36933300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disability progression in aggressive multiple sclerosis.
    Menon S; Zhu F; Shirani A; Oger J; Freedman MS; Tremlett H
    Mult Scler; 2017 Mar; 23(3):456-463. PubMed ID: 27325603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
    Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
    JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.
    Palace J; Duddy M; Bregenzer T; Lawton M; Zhu F; Boggild M; Piske B; Robertson NP; Oger J; Tremlett H; Tilling K; Ben-Shlomo Y; Dobson C
    Lancet Neurol; 2015 May; 14(5):497-505. PubMed ID: 25841667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time between expanded disability status scale (EDSS) scores.
    Zurawski J; Glanz BI; Chua A; Lokhande H; Rotstein D; Weiner H; Engler D; Chitnis T; Healy BC
    Mult Scler Relat Disord; 2019 May; 30():98-103. PubMed ID: 30763908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs.
    Degli Esposti L; Piccinni C; Sangiorgi D; Perrone V; Aledda L; Marrosu MG; Lombardo F
    Neurol Sci; 2017 Apr; 38(4):589-594. PubMed ID: 28078563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.
    Ribbons KA; McElduff P; Boz C; Trojano M; Izquierdo G; Duquette P; Girard M; Grand'Maison F; Hupperts R; Grammond P; Oreja-Guevara C; Petersen T; Bergamaschi R; Giuliani G; Barnett M; van Pesch V; Amato MP; Iuliano G; Fiol M; Slee M; Verheul F; Cristiano E; Fernandez-Bolanos R; Saladino ML; Rio ME; Cabrera-Gomez J; Butzkueven H; van Munster E; Den Braber-Moerland L; La Spitaleri D; Lugaresi A; Shaygannejad V; Gray O; Deri N; Alroughani R; Lechner-Scott J
    PLoS One; 2015; 10(6):e0122686. PubMed ID: 26046348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Russo CV; Triassi M; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2016 Nov; 10():90-96. PubMed ID: 27919507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.